Biocon published its financial results for a quarter ending on June 30 with 15% year -on -year on £3 942 Crore, driven by profits in its Biosimilars and CRDMO businesses.
Its net profit dropped by 95% compared to the same quarter in the previous year due to a one -off profit from the sale of its branded formulations in Q1FY25.
Biocon’s net profit for the quarter was at £31 crore, compared to £660 crore in Q1FY25. With the exception of profit sales from Q1FY25, its profit increased by 65%, the company said.
The income and profit based on Bengalur have missed the street estimates. Bloomberg survey of 11 brokers hung their income on £4 024 crore and profit after tax on £111.7 crore.
The company reported EBITDA £829 crore, year -on -year by 53%. With the exception of profit, its EBITDA increased by 19%, the company said. EBITDA margins decreased to 21% of 38% in the same period last year.
Biosimilars Business, which represents 61% of its total income, has published revenue £2 458 crore, year -on -year 18%.
Generics Business has published revenue £697 crore, 6% year -on -year, and CRDMO business, under Sygene International, published growth by 11% on £875 crore.
“Biocon opened FY26 with strong power, powered by continuing profits in Biosimilars and CRDMO, and a permanent performance in generics. Operating revenues increased by 15% £3 942 Crore, with EBITDA O 19% on the basis of a similar similar one, shows the operating lever and the robustness of our businesses, ”said Kiran Mazumdar-Shaw, chairman of the Biocon Group.
A successful increase of qip
The company has risen during the quarter £4,500 Crore through a qualified institutional location (QIP). Funds will be used to increase Biocon’s possession in its subsidiary biological biology and providing the departure to private capital investors, the company said.
“The recent QIP has strengthened our balance sheet and allows us to increase our ownership in biological biology by facilitating the departure of structured capital investors and tending the capital structure with long -term strategic priorities,” Shaw said.
In the last quarter, Biocon said that his council was established by the Committee on the evaluation of the merger of biological biology with the parent company.
During the quarter, the company launched its tenth global biosimilar, Yesafili, which is used to treat ophthalmological conditions in Canada, and received USFDA approval for Aspart’s insulin.
(Tagstotranslate) Biocon (T) Drugmaker Bengaluru (T) Biosimilars Business (T) Generics Business (T) Syngene International (T) CRDMO Business (T) Kiran Mazumdar-Shaw (T) (T) the Unsilulika
